About: COVID-19 Vaccine Candidates: Prediction and Validation of 174 SARS-CoV-2 Epitopes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 Vaccine Candidates: Prediction and Validation of 174 SARS-CoV-2 Epitopes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 Vaccine Candidates: Prediction and Validation of 174 SARS-CoV-2 Epitopes
Creator	Jurgons, Erik Justesen, Sune Otzen Bagger, Frederik Prachar, Marek Steen-Jensen, Daniel Thorgrimsen, Stephan Winther, Ole
Source	BioRxiv
abstract	The recent outbreak of SARS-CoV-2 (2019-nCoV) virus has highlighted the need for fast and efficacious vaccine development. Stimulation of a proper immune response that leads to protection is highly dependent on presentation of epitopes to circulating T-cells via the HLA complex. SARS-CoV-2 is a large RNA virus and testing of all overlapping peptides in vitro to deconvolute an immune response is not feasible. Therefore HLA-binding prediction tools are often used to narrow down the number of peptides to test. We tested 19 epitope-HLA-binding prediction tools, and using an in vitro peptide MHC stability assay, we assessed 777 peptides that were predicted to be good binders across 11 MHC allotypes. In this investigation of potential SARS-CoV-2 epitopes we found that current prediction tools vary in performance when assessing binding stability, and they are highly dependent on the MHC allotype in question. Designing a COVID-19 vaccine where only a few epitope targets are included is therefore a very challenging task. Here, we present 174 SARS-CoV-2 epitopes with high prediction binding scores, validated to bind stably to 11 HLA allotypes. Our findings may contribute to the design of an efficacious vaccine against COVID-19.
has issue date	2020-04-06(xsd:dateTime)
bibo:doi	10.1101/2020.03.20.000794
has license	biorxiv
sha1sum (hex)	26acc21ff1ff247b60faee34ceff9ac38d52ad21
schema:url	https://doi.org/10.1101/2020.03.20.000794
resource representing a document's title	COVID-19 Vaccine Candidates: Prediction and Validation of 174 SARS-CoV-2 Epitopes
schema:publication	bioRxiv
resource representing a document's body	covid:26acc21ff1ff247b60faee34ceff9ac38d52ad21#body_text
is schema:about of	named entity 'HLA' named entity 'number' named entity 'potential' named entity 'vaccine' named entity 'SARS-CoV-2' named entity 'OUR' named entity 'RNA VIRUS' named entity 'USED' named entity 'ASSAY' named entity 'TARGETS' named entity 'FEASIBLE' named entity 'VIRUS' named entity 'FAST' named entity 'performance' named entity 'narrow' named entity 'epitope' named entity 'immune response' named entity 'efficacious' named entity 'targets' named entity 'deconvolute' named entity 'SARS-CoV-2' named entity 'allotype' named entity 'T-cells' named entity 'MHC' named entity 'virus' named entity 'MHC' named entity 'immune response' named entity 'HLA' named entity 'peptides' named entity 'peptides' named entity 'Epitopes' named entity 'SARS-CoV-2' named entity 'DNA sequence' named entity 'specific weight' named entity 'HLA' named entity 'alleles' named entity 'web server' named entity 'vaccine design' named entity 'HLA' named entity 'Peptides' named entity 'COVID-19' named entity 'peptide' named entity 'HLA' named entity 'vaccine' named entity 'allotype' named entity 'WHO' named entity 'peptides' named entity 'vaccine' named entity 'allotype' named entity 'diethylether' named entity 'SARS-CoV-2 virus' named entity 'urea' named entity 'immune response' named entity 'vaccine' named entity 'peptides' named entity 'peptide' named entity 'denatured' named entity 'peptides' named entity 'allotype' named entity 'epitopes' named entity 'epitopes' named entity 'MHC' named entity 'AUC' named entity 'Area Under Curve' named entity 'denaturation' named entity 'peptides' named entity 'China' named entity 'proteome' named entity 'HLA-A' named entity 'allotype' named entity 'class II' named entity 'HLA-A' named entity 'vaccine' named entity 'early stopping' named entity 'SARS' named entity 'SARS-CoV-2' named entity 'allotype' named entity 'NCBI'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software